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The ability to attract sufﬁcient resources to effectively develop therapeutics for rare diseases is a daunting task.
This review summarizes existing resources for rare diseases and discusses some of the challenges and strategies
associated with developing therapies for small patient populations with an emphasis on pachyonychia congenita.
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A rare (orphan) disease is defined under the United States
Orphan Drug Act amendment (Orphan Drug Act, P.L. 97–414
(1983); Health Promotion and Disease Prevention Amend-
ments, P.L. 98–551 (1984)) as a disorder that generally af-
fects less than 200,000 individuals (  0.07% of the US
population). The definition is extended to disorders that af-
fect greater numbers of individuals for which drug devel-
opment is not likely, due to the expectation that the sales of
such a drug would not be sufficient to recover development
costs. Similar rare disease definitions are used by other
countries including the European Community, Japan,
Singapore and Australia (see the websites, http://www.
rare-cancer.org/rare-diseases.html and http://www.europarl.
eu.int/stoa/publi/167780/chap5_en.htm).
Approximately 6,000 rare diseases have been identified
and a list is maintained by the Office of Rare Diseases (ORD)
at the National Institutes of Health (NIH) (http://ord.aspensys.
com/asp/diseases/diseases.asp). Some of the listed rare
diseases are well-known, such as sickle cell anemia, Hunt-
ington disease, cystic fibrosis, Lou Gehrig disease, and
Tourette syndrome, whereas most are less familiar including
pachyonychia congenita (PC). Many rare diseases have
patient populations of fewer than a hundred (http://
www.fda.gov/fdac/features/2003/603_orphan.html).
Although the incidence of an individual rare disease is
small, cumulatively the 6,000 known rare diseases affect 25
million Americans or nearly 10% of the US population (Ra-
dos, 2003). The majority of rare diseases, including PC,
have a genetic origin component, have little or no treatment
options, and are not rigorously studied. The number of PC
patients worldwide is currently unknown, but is likely to be
on the order of 1,000–10,000 patients (Sancy Leachman,
personal communication; see also http://www.emedicine.
com/derm/topic812.htm).
Costs of Developing Therapeutics
According to a widely accepted study performed by DiMasi
et al (2003), the estimated average out-of-pocket cost for
bringing a new drug to market is $403 million (year 2000, US
dollars). When investment and capitalization costs are in-
cluded this estimate rises to $802 million. A more recent
study by Bain & Co. put the costs at $1.7 billion (Gilbert
et al, 2003; Mullin, 2003). Regardless of the actual costs,
these impressively large numbers, coupled with the obser-
vation that only 21% of drugs that enter phase I clinical trials
make it to the marketplace, underscore the difficulty of en-
ticing the investment community to fund research for rare
diseases for which recovery of development costs seems
unlikely. In a marketplace where the business model has
historically been on blockbuster drugs that generate over a
billion dollars in annual sales, there has been reluctance
among large pharmaceutical companies and the investment
community to pursue small market therapeutics.
Resources Available to Stimulate Rare
Disease Research
Perhaps the most important governmental act that stimu-
lated research and development of rare disease therapeu-
tics was passage of the 1983 Orphan Drug Act. This
program provided financial incentives to develop treatments
for rare diseases, including a guarantee of a 7-y period of
market exclusivity, tax credits for clinical research, and
waiver provisions for license fees. The Orphan Drug Act has
been successful in stimulating development of rare disease
drugs (Fig 1) by small and medium-sized biotechnology
companies—more than 200 drugs and biological products
for the treatment of rare diseases have been brought to
market since its passage in 1983. In contrast, in the 10 y
prior to its passage, fewer than ten rare disease products
came to the market (Rohde, 2000; Lichtenberg and Waldfo-
gel, 2003; see also http://www.fda.gov/orphan). European
Abbreviations: FDA, Food and Drug Administration; NIH, National
Institutes of Health; ORD, Office of Rare Diseases; PC, pachyo-
nychia congenita
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Orphan Medicinal Drug Product legislation similarly pro-
vides financial incentives (Milne et al, 2001).
Recognizing the need to address the 25 million Ameri-
cans afflicted with a rare disease, the US Congress es-
tablished The ORD in 1993 to promote research and
collaborative efforts. H.R. 4014 (2002) gave statutory sta-
tus to the ORD at the NIH. The ORD provides information on
rare diseases, and links investigators with research subjects
and patients, and supports rare disease research (Rados,
2003). In addition, the ORD funds research into rare dis-
eases directly or in combination with other NIH Institutes.
Furthermore, in 2003 a Rare Diseases Clinical Research
Network was established, which includes seven Rare Dis-
eases Clinical Research Centers spread throughout the
United States (see website: http://rarediseases.info.nih.gov/
html/resources/extr_res.html). This Network maintains a
database of clinical trials for rare diseases and refers rare
disease patients to appropriate medical care.
Other organizations have been formed to facilitate infor-
mation flow and research and development of rare disease
therapeutics. The National Organization of Rare Diseases
(NORD) is a federation of approximately 125 voluntary
health organizations and over 60,000 patients (http://
www.rarediseases.org/). The International Rare Disease
Support Network (IRDSN) offers support groups for over
1200 diseases (http://www.raredisorders.com/). OrphaNet
provides information on rare diseases (http://www.
orpha.net/consor/cgi-bin/home.php?Lng=GB). The European
Rare Disease Therapeutic Initiative (ERDITI, http://www.
erditi.org/) is a coalition of patient organizations fostering
interactions between academic institutions working on rare
diseases and the pharmaceutical industry to bring new
therapeutics to the marketplace. Similarly, the Office of Or-
phan Products Development (OOPD, http://www.fda.gov/
orphan/progovw.htm) at the US Food and Drug Adminis-
tration (FDA) and Public Health Programme (formerly
The EU Programme on Rare Diseases, http://europa.
eu.int/comm/health/ph_overview/previous_programme/rare_
diseases/rarediseases_en.htm) facilitate orphan drug de-
velopment through guidance and financial assistance (see
Fig 2). The National Center For Study of Orphan Disease
(CSOD, http://www.csod.us/) bridges various organizations
to facilitate rare disease therapeutic development.
Justiﬁcation of Research Dollars for
Rare Diseases
Given the current high cost of bringing a new drug to market
(see above), the difficult question arises regarding at what
level it becomes financially feasible to fund research that
benefits a relatively small group of patients with a given rare
disease. If the costs of developing a therapeutic to treat a
disease that afflicts 10 million people is approximately the
same as a distinct therapeutic that would treat 100,000 (or
100), how can the high cost of developing a therapeutic for
a rare disease be justified?
A study by Love and Palmedo (Consumer Project on
Technology, (see website: http://www.cptech.org/ip/health/
orphan/irsdata9798.html) challenges the reported high de-
velopment costs associated with rare disease drug discov-
ery. Taking into account the amount US taxpayers received
as tax credits (50% credit allowed) for orphan disease clin-
ical development ($141 million for 1997 and 1998, the most
recent data available), they calculated the cost for clinical
development, testing and marketing of the 36 orphan
products approved during the same time period to be
$7.9 million per orphan product ($283 million/36 products)
before tax, and $3.9 million with the benefits of the orphan
drug tax credit.
A number of biotechnology companies have taken ad-
vantage of the Orphan Drug Act financial incentives to spe-
cifically develop and market therapeutics for the rare
disease market. Several companies have profitably target-
ed this niche market. Approximately half of Genzyme’s 2003
revenue came from $740 million in sales of Cerezyme
(Genzyme, Cambridge, MA). This is an enzyme replacement
therapy for Gaucher disease, a potentially deadly genetic
Figure 1
Orphan drug approval. Cumulative number of orphan drugs approved
from 1979 through 1998 as compared to cumulative number of total
drugs approved. The Orphan Drug Act was passed in 1983. Graph
reproduced with permission from Lichtenberg (Lichtenberg and
Waldfogel, 2003).
Figure2
Flowchart of milestones leading to approval of pachyonychia con-
genita (PC) therapeutic. New orphan drug development process. Ap-
plication for orphan drug status (for therapeutics being developed for
diseases afflicting fewer than 200,000 patients) can be made at any
time prior to new drug application (NDA) application. The Food and
Drug Administration (FDA) Office of Orphan Products Development
(OOPD) helps facilitate orphan disease product development and en-
courages interaction between sponsor, FDA and OOPD at various
stages of the process including prior to application for orphan drug
status. Figure was modified (with permission) from the FDA website
(http://www.fda.gov/cder/handbook/develop.htm).
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disorder that causes anemia and enlarged organs (http://
www.genzyme.com). Gaucher disease affects less than
10,000 people worldwide and about 40% are treated with
Cerezyme. Although the 7 y marketing exclusivity of Cere-
zyme has long since ended, the drug remains entrenched in
the marketplace and highly profitable. Much of the remain-
der of Genzyme’s sales comes from other therapeutics with
current orphan drug status including Fabrazyme (for Fabry
disease), Aldurazyme (for Mucopolysaccharidosis I), and
Thyrogen (for thyroid cancer). Other companies including
Transkaryotic Therapies (Cambridge, MA), Oxford Glyco-
Sciences (Brussels, Belgium), and Orphan Medical (Minne-
tonka, MN) have also taken a similar approach to seek niche
markets for specific rare diseases, taking advantage of
the Orphan Drug Act. Many current blockbuster drugs
(sales over $1 billion per year), including Amgen’s Epogen
and Neupogen, were originally introduced as orphan drug
products and were later extended to larger markets.
Societal Beneﬁts of Rare Disease Research
Why treat rare diseases, particularly diseases in which very
small numbers of patients are involved? There are several
answers to this question, not the least of which is that these
are real people with families and employers that are also
affected by the loss of quality of life and productivity. Fur-
thermore, science is replete with examples of esoteric re-
search that has led to unintended discoveries that benefit
society at large. Basic research is funded with the expec-
tation that investigation in one area will have benefits in
many related as well as unrelated and unexpected areas.
The study of rare diseases has often yielded great amounts
of information, completely out of proportion with the
number of patients suffering from the disorder. William Ha-
rvey, the English physician and discoverer of blood circu-
lation, stated in a letter dated 1657, ‘‘Nature is no where
accustomed more openly to display her secret mysteries
than in cases where she shows traces of her workings apart
from the beaten path; nor is there any better way to ad-
vance the proper practice of medicine than to give our
minds to the discovery of the usual law of nature, by careful
investigation of cases of rarer forms of disease. For it has
been found in almost all things that what they contain of
useful or applicable, is hardly perceived unless we are de-
prived of them, or they become deranged in some way
(Willis, 1847; Zelzer and Olsen, 2003).’’
The majority of rare diseases are due to genetic muta-
tions. In many cases, these mutations affect a single gene
and cause perturbations in a metabolic pathway. This rare
disease datasource has been a rich resource from which a
great deal has been learned about normal human metab-
olism, since the study of aberrant metabolism (i.e., blockage
of a single step in a metabolic pathway due to the absence
of a functional gene) teaches a great deal regarding how
normal pathways function. These ‘‘natural’’ experiments are
similar to carefully controlled knockout animal experiments
in which the function of single genes are analyzed and often
give major insights into metabolic pathways.
There are numerous examples in which rare disease re-
search has led to insights into more general disease proc-
esses. For instance, it would have been difficult to predict
that study of kuru, a mental illness in a New Guinea tribe,
one symptom of which is uncontrollable laughter, would
lead to the discovery of a new class of contagion and result
in a Nobel prize for Stanley Prusiner (Prusiner, 1984). The
discovery that the disease-causing prions were passed
along by consumption of the brains of deceased relatives
allowed the discovery of the prion cause of other rare
diseases including Creutzfeldt–Jakob and Gertsmann–
Straussler–Scheinker (GSS) syndrome, as well as recogniz-
ing that bovine spongiform encephalopathy (BSE), was
caused by ingestion of contaminated beef. This pioneering
work likely resulted in an epidemic being averted and thou-
sands of lives spared. Another example is a-1-antitrypsin
deficiency, a rare genetic emphysema lung disease that
develops 10–30 y before the occurrence of the more com-
mon form found in smokers. The earlier onset has allowed
researchers to study the disorder in the absence of com-
pounding factors due to smoking and aging, leading to in-
sights into emphysema (Rados, 2003).
Leveraging Existing Resources
PC is an excellent example of a rare disease that could
serve as a model for a multitude of other skin disorders and/
or autosomal dominant disorders. As discussed above and
in other reports in this issue, the specific mutations in ker-
atin genes K6a/b, K16 and K17 responsible for PC have
been identified (Munro, 2001; Terrinoni et al, 2001; Smith,
2003). Furthermore, the skin cell type involved (keratinocyte)
is known and is readily accessible. Therefore, this disorder
could serve as a paradigm for many other keratinocyte skin
disorders, including psoriasis and epidermolysis bullosa
(Porter and Lane, 2003; Sawamura et al, 2003). Technolo-
gies including siRNA, ribozymes, and antisense have been
shown to specifically block expression of target genes in
many systems (see Lewin et al, this issue) including kera-
tinocytes (Mehta et al, 2000; Arts et al, 2003; Barbieri et al,
2003; Seo et al, 2004). The main remaining hurdle for clinical
application is efficient delivery to the appropriate cells. De-
velopment of a skin delivery system in an ‘‘easy to work
with’’ system would be a boon to treatment of other skin
disorders. PC may represent one of the ‘‘most straightfor-
ward’’ genetic disorders for treatment due to the accessi-
bility of the skin. Furthermore, complete blockage or
removal of a mutant keratin gene may not be necessary
as a partial reduction may be sufficient to give a therapeutic
effect (see discussion of K10/K14 in Chen and Roop, this
issue). Unlike psoriasis, which involves multiple cell types
including keratinocytes and immune cells (Kirby and
Griffiths, 2002; Barry and Kirby, 2004), PC appears to be
limited to keratinocytes. Finally, the difficulty of discrimina-
tion between mutant and wild-type genes, likely to be nec-
essary for most genetic diseases, does not appear to be a
requisite for an effective PC treatment. Reduction of both
the wild-type and mutant keratin gene products is likely to
give a therapeutic effect as other ‘‘redundant’’ keratin pairs
will likely compensate for the missing mutant keratin gene
pair (see Lewin et al, in this issue).
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Bringing Together Existing Expertise and
Resources for Rare Disease Therapeutic
Development
The Pachyonychia Congenita Public Charity was formed
with the aim to develop an effective therapeutic for the rel-
atively small number of patients suffering from PC (http://
www.pachyonychia.org/index.html). To this end, a consor-
tium of investigators was brought together with medical and
scientific expertise in various areas related to PC and tech-
nology that may be useful in developing PC therapeutics.
The Public Charity has provided seed funding to allow tar-
geted research that should facilitate progress towards PC
therapeutic development (see Introductory PC article in this
issue). The collaborative nature of the consortium is essen-
tial to prevent wasteful redundant research and allow effi-
cient use of limited resources. Furthermore, the breadth of
the expertise of the consortium membership will allow con-
tinual monitoring of scientific and medical progress of
related skin disorders, ideally taking advantage of and
building on breakthroughs including new skin delivery
systems.
In addition to the Pachyonychia Congenita Public Char-
ity, other private organizations and philanthropic individuals,
public resources are available for rare diseases research
and clinical development and testing including the NIH
R21 Exploratory and Development (http://grants1.nih.gov/
grants/guide/pa-files/PA-03-171.html) and U54 (http://grants.
nih.gov/grants/guide/rfa-files/RFA-RR-03-008.html) grant
mechanisms. Furthermore, the FDA administers a program
to fund clinical trials for drugs that have achieved orphan
drug status (see website: http://www.fda.gov/orphan/
grants/2004RFA.htm).
Other Considerations
As discussed in other reports in this PC JID edition, the ideal
solution for a permanent cure for PC would be a gene ther-
apy replacement procedure in which the defective PC gene
would be replaced with a corrected version that would be
regulated in identical fashion to the wild-type gene. This
‘‘gold standard’’ gene replacement therapy has not been
approved for any disorder to date and will likely be initially
applied to acute, life threatening, ‘‘no alternative’’ diseases.
The amount of development and testing required, as well as
its non-life threatening nature, makes PC an unlikely early
candidate for gene therapy. On the other hand, PC is a
straightforward dominant-negative genetic skin disorder in
which the responsible gene mutations have been identified.
Animal experiments suggest that therapeutic benefits may
accrue from simple downregulation of the mutant gene.
Surprisingly, downregulation of the wild-type K6a gene
does not result in apparent skin structural defects, as other
related keratin gene pairs appear to compensate for the
deficiency (Wojcik et al, 2000; Wojcik et al, 2001), see also
Chen and Roop, in this issue. Therefore, as replacement
gene therapy technology improves and safer human gene
delivery vehicles are developed, PC will be an ideal gene
therapy candidate. In the short run, however, non-viral de-
livery of potent specific keratin inhibitors, preferably deliv-
ered topically to avoid systemic side effects, appears to be
the most promising approach from a practical, regulatory,
ethical and economical standpoint.
Conclusions
Personalized molecular medicine: the end of rare dis-
eases? With the advent of new technologies including mi-
croarray chips that can detect steady-state levels of tissue
mRNA including single nucleotide mutations, the era of
personalized molecular medicine appears imminent (Jain,
2002, 2004). Powerful technologies continue to be devel-
oped that can specifically target and block expression of
specific genes (the latest being RNA interference or siRNA
(Dave and Pomerantz, 2003; Alisky and Davidson, 2004;
Caplen, 2004; see also Lewin et al, in this issue). As
progress continues in the arena of specific and safe delivery
vectors for correcting genes or delivering siRNA or other
gene-specific inhibitors directly, one can envision a scenario
in which diagnosis of overexpressed genes involved in rare
diseases is readily translated into designer molecular med-
icines that specifically target these problem genes. If the
delivery issue can be solved, theoretically any gene can be
targeted and its protein product blocked or reduced, pro-
viding a therapeutic effect. Specifically targeting problem-
atic single nucleotide mutations in disease-causing genes
will likely prove more difficult and may require improved
technology. Some diseases, such as PC, however, may not
suffer from this discrimination difficulty as concomitant re-
duction of the wild-type gene is unlikely to affect the ther-
apeutic outcome as other keratin gene pairs may
compensate as a result of redundancy in the system (Wong
et al, 2000; Wojcik et al, 2001; Wong and Coulombe, 2003).
This advantage, coupled with relatively easy access to the
diseased cells (skin keratinocytes), makes PC an excellent
candidate disorder for treatment with specific and robust
nucleic acid therapeutics such as siRNA.
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